Vaccinia Virus Induces Strong Immunoregulatory Cytokine Production in Healthy Human Epidermal Keratinocytes: a Novel Strategy for Immune Evasion

Citation

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41483424

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Vaccinia Virus Induces Strong Immunoregulatory Cytokine Production in Healthy Human Epidermal Keratinocytes: a Novel Strategy for Immune Evasion

Luzheng Liu, Zhan Xu, Robert C. Fuhlbrigge, Victor Peña-Cruz, Judy Lieberman, and Thomas S. Kupper

Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; CBR Institute for Biomedical Research, Boston, Massachusetts; and Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, Massachusetts

Received 4 November 2004/Accepted 8 February 2005

Iatrogenic cutaneous infection with vaccinia virus (VV) and naturally occurring systemic infection with variola virus both lead to the characteristic skin “pox” lesions. Despite significant medical experience with both viruses, surprisingly little is understood about the interactions between these poxviruses and healthy resident skin cells. In recent years, it has become clear that skin plays an essential role in modulating both innate and adaptive immune responses, in part by producing and responding to a variety of cytokines and chemokines upon stimulation. Antagonists of many of these compounds are encoded in poxivirus genomes. Infection of skin cells with poxviruses may lead to a unique pattern of cytokine and chemokine production that might alter the cutaneous immune surveillance function. In this study, we infected primary cultures of human skin cells with VV and monitored antigen expression, virus replication, and cytokine production from the infected cells. While T cells, Langerhans cells, and dermal dendritic cells were infected abortively, keratinocytes, dermal fibroblasts, and dermal microvascular endothelial cells (HMVEC-d) all supported the complete virus life cycle. In contrast to the robust viral replication in fibroblasts and HMVEC-d, only limited viral replication was observed in keratinocytes. Importantly, VV infection of keratinocytes led to up-regulation of immunoregulatory and Th2 cytokines, including transforming growth factor β, interleukin-10 (IL-10), and IL-13. We propose that the rapid induction of keratinocyte Th2 and immunoregulatory cytokines represents a poxvirus strategy to evade immune surveillance, and the limited viral multiplication in keratinocytes may be a protective mechanism to help the immune system “win the race.”

In recent years, accumulating evidence has revealed that in addition to providing the physical barrier between the body and the environment, skin cells can actively modulate both innate and adaptive immune responses, in part by producing and responding to a variety of cytokines and chemokines upon stimulation. While the cytokine and chemokine production in skin, especially in keratinocytes, has been shown to be important in contact hypersensitivity responses, chronic skin inflammatory diseases, and cutaneous malignancies, little has been done to investigate the immunological response of resident skin cells upon viral infections (23, 37, 41, 45). Of particular interest to us is cutaneous infection by poxviruses. Poxviruses have been shown to enter their hosts either by the respiratory route or through the skin. Natural infection with many poxviruses leads to the characteristic skin “pox” lesions, and the severity of infection varies dramatically from one species to another, causing anywhere from a local, self-limited infection to a devastating systemic disease, such as smallpox (40). In humans, inoculation of vaccinia virus (VV) through the epidermis leads to successful immunization against smallpox in the majority of the vaccinees (44). However, serious adverse responses are not uncommon, especially in patients with pre-existing immune abnormalities (25). One complication, eczema vaccinatum, occurs primarily in patients with atopic dermatitis, a chronic inflammatory skin condition affecting 5 to 15% of the pediatric population and somewhat fewer adults. Atopic dermatitis is associated with a Th2-dominated dysregulation of cytokine production (1, 15). These observations suggest that the skin microenvironment is crucially involved in the development of protective immune responses as well as pathological reactions following poxvirus infection. Studying the interaction between VV and skin cells is therefore critical for the understanding of the immunogenicity as well as the pathogenesis of adverse responses following VV scarification. Knowledge gained from these studies will be valuable for the development of optimal poxvirus-based vaccines that are both safe and effective, even for patients with defective immunity.

Like other poxviruses, VV has been shown to utilize multiple immune evasion strategies to negatively modulate the host immune response (40). Multiple early VV gene products are directed at inhibiting the innate immune response (2–4). The adaptive immune response is also targeted. Th1 cytokines such as tumor necrosis factor alpha (TNF-α) and gamma interferon (IFN-γ) have been found to play an integral role in controlling vaccinia virus infections, by enhancing CD8+ T-cell-mediated cytotoxic function and directly inhibiting viral replication. Sol-
uble antagonistic receptor homologues for TNF-α and IFN-γ are produced by VV-infected cells (36). Conversely, the Th2 cytokines seem to be permissive for poxvirus replication, as insertion of interleukin-4 (IL-4) in the mousepox genome rendered a genetically resistant strain of mice susceptible to the lethal viral challenge (19). It is unknown whether VV infection of target cells could alter the Th2 cytokine production or function. We hypothesize that infection of skin cells by VV may lead to a unique pattern of cytokine and chemokine production that could inhibit the virus-controlling Th1 response and favor the development of a Th2 response.

To explore these issues, we infected primary cultures of isolated human skin cells with VV, including keratinocytes, dermal fibroblasts, dermal microvascular endothelial cells (HMVEC-d), Langerhans cells (LC), dermal dendritic cells (DC), and skin-homing cutaneous leukocyte antigen (CLA)-positive T cells (16). Viral antigen expression and replication, as well as the cytokine production profile, were monitored in the infected cells. We show that VV infects skin cells of both hematopoietic origin and nonhematopoietic origin, but the infection is abortive in the former cell types and productive in the latter. To our surprise, VV replicates only at a low level in keratinocytes, in contrast to the robust viral replication in dermal fibroblasts and endothelial cells. Most importantly, while vaccinia virus infection of HMVEC-d led to a general “shutdown” of cytokine and chemokine expression, VV induced multiple immunoregulatory cytokines in the infected keratinocytes, including the negative immunoregulatory and Th2 cytokines transforming growth factor β (TGF-β), IL-13, and IL-10. These results suggest a novel immune evasion mechanism employed by poxviruses to skew local cytokine production against the generation of protective Th1 and cytotoxic T-lymphocyte (CTL) responses. In the case of VV infection, these strategies are insufficient to permit unrestrained viral growth in most immunocompetent individuals. However, in immunocompromised patients and those with a preexisting predilection towards generating Th2 responses, they may enable this usually innocuous virus to overwhelm immune defenses and cause serious diseases.

### MATERIALS AND METHODS

**Cells.** Healthy human skin was obtained as discarded material from facelift surgery or reduction mammoplasty in accordance with the policies of the human research committee of Brigham and Women’s Hospital, Boston, MA. Primary human keratinocyte cultures were generated as described previously, with slight modification as noted (8). Briefly, small skin pieces were incubated at 37°C for 1 h with 1.2 U/ml grade II dispase (Roche, Indianapolis, IN) in complete RPMI 1640 medium. Epidermis was gently teased away from dermis and incubated in 0.25% trypsin-0.1% EDTA for 5 min at 37°C to dissociate cells. Following centrifugation for 5 min at 300 × g, the cells were resuspended and plated in Gibco keratinocyte-sfm culture medium (see below), and exponentially growing cultures at approximately 30% confluence were used for serial passage. Keratinocyte differentiation was induced by culturing the cells in the presence of 1.5 mM calcium. Dermal fibroblasts were isolated from dermis by collagenase (90 U/ml) digestion and cultured in DF12 medium (see below). HMVEC-d cells were expanded from cryo-preserved cells in EGM-2-MV medium (CC-3202; Cambrex BioScience) according to the vendor’s instructions. All cultures were maintained at 5% CO₂ and 37°C. The cells were plated in six-well culture plates 1 or 2 days prior to infection.

Immature LC were isolated from healthy skin by discontinuous density gradient as described elsewhere (35). Mature LC and dermal DC were obtained by cell migration from epidural and dermal sheets, respectively, as previously described (34). The purity of the cell populations was generally >90%, as determined by flow cytometry (data not shown). The immature LC were CD1a<sup>hi</sup>, CD3<sup>+</sup>, and HLA-DR<sup>hi</sup>, the mature LC were CD3<sup>+</sup> and HLA-DR<sup>hi</sup>, and the dermal DC were CD1a<sup>hi</sup>, CD3<sup>+</sup>, and HLA-DR<sup>hi</sup> (data not shown). The isolated cells were kept in complete RPMI 1640 and used within 12 h. Total CD3<sup>+</sup> T cells were puriﬁed from healthy human peripheral blood mononuclear cells by using a pan T-cell isolation kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions. Cell purity was typically >90% as determined by flow cytometry (data not shown). CLA<sup>+</sup> T cells were puriﬁed by magnetic bead separation from the above CD3<sup>+</sup> T cells using rat anti-human CLA monoclonal antibody (MAB) HECA 452 (BD Pharmingen, San Diego, CA) followed by mouse anti-rat kappa microbeads (Miltenyi Biotec). Antibodies not provided in isolation kits were purchased from BD Pharmingen. The purity of CLA<sup>+</sup> T cells was typically over 85% by flow cytometry analysis. The African green monkey kidney ﬁbroblast cell line, CV-1, was a kind gift from Judy Liebermann (Center for Blood Research, Boston, MA) and was maintained in complete Dulbecco’s modiﬁed Eagle’s medium (DMEM).

**Cell culture medium.** Complete RPMI 1640 medium is RPMI 1640 (Invitrogen, Grand Island, NY) supplemented with 10% fetal calf serum (FCS), 100 IU/ml penicillin, 2 mM l-glutamine, 100 µg/ml streptomycin, and 0.5 mg/ml amphotericin. Gibco keratinocyte-sfm culture medium was supplemented with 25 µg/ml bovine pituitary extract and 0.2 ng/ml epidermal growth factor (EGF; Invitrogen, Grand Island, NY) plus 0.3 mM CaCl<sub>2</sub> and antibiotics (39). DF12 medium is a 1:1 mixture of DMEM and F-12 medium (Mediatech, Herndon, VA) supplemented with 15% FCS, 10 ng/ml EGF, and antibiotics. Complete DMEM is DMEM supplemented with 10% FCS, 2 mM l-glutamine, and antibiotics.

**Viral stock and infection.** Wild-type Western Reserve strain VV (WR-VV) was a kind gift from N. Manjunath (Center for Blood Research, Boston, MA). The viral stock was expanded and the titers were determined on CV-1 cells by standard procedures (13). Cells were cultured in six-well plates to reach ~85 to 95% confluence and infected with WR-VV at the indicated multiplicity of infection (MOI) in 0.5 ml/well of culture medium for 1 h. The cultures were then brought to 2 ml of medium/well and incubated for additional time periods as indicated before harvesting.

**Immunostaining for viral gene expression and flow cytometry.** Mouse MAb TW2.3 and rat MAB19C2, recognizing early viral antigen (Ag) E3L and late viral Ag BSF, respectively (38, 47) (kind gifts from Bernard Moss, National Institutes of Health), were used to detect vaccinia virus gene expression in the infected cells. Cells were permeabilized and fixed with CytoPerm/CytoFix (BD Pharmingen) and incubated with the above Abs for 30 min on ice, followed by labeling with fluorescein isothiocyanate-conjugated goat-anti-mouse immunoglobulin G (Southern Biotechnology Associates, Inc., Birmingham, AL). Samples were then processed using a FACS-Calibur flow cytometer (Becton Dickinson Labware), and the data were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).

**Plaque assay to determine viral replication.** Cells were cultured in six-well plates to reach 85 to 95% confluence. Two extra wells of each cell culture were used to obtain cell number per well. The cultures were then infected with WR-VV at an MOI of 0.1 or 10 for 60 h. Cells were harvested and suspended in 200 µl 10 mM Tris buffer (pH 8) before lysis by three freeze-thawing (dry ice-ethanol) and thawing (37°C water bath) cycles. The titer of vaccinia PFU per sample was determined by standard plaque assay on CV-1 monolayers (13). The PFU per cell was calculated as PFU per sample per number of cells at the beginning of the infection.

**MicroSpot ELISA array to measure cytokine production from infected cell cultures.** Cells were infected with WR-VV at an MOI of 10 for 24 h, and supernatant samples were collected and stored at −80°C until analysis. Uninfected culture supernatant samples were collected as controls. The concentrations of 16 cytokines in the supernatant samples were measured simultaneously with the MicroSpot enzyme-linked immunosorbent assay (ELISA) array technology at the Schleicher & Schuell Protein Array Facility (Schleicher & Schuell, Keene, NH) (21, 42). All the samples were processed simultaneously in triplicate. Briefly, capture MABs for human IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p40, IL-12 p70, IL-13, IFN-γ-inducible protein 10 (IP10), soluble intercellular adhesion molecule 1 (sICAM-1), TNF receptor II (TNFR II), TNF-α, IFN-γ, vascular endothelial growth factor (VEGF), and TGF-β were arrayed on the three-dimensional nitrocellulose surface of the FAST slide. Supernatant samples and serial dilutions of cytokine standard cocktail were added (70 µl/pad) onto the slide, which was incubated for 3 h on an orbital shaker at room temperature followed by three washes. The biotinylated detection antibody cocktail was then added (70 µl/pad) onto the FAST slide. Following 1 h of incubation on the orbital shaker and three washes, 0.125 µg/ml reporter molecule streptavidin-Cy5
was added and the slide was incubated in the dark for 45 min. After three washes, the slide was quickly rinsed, air dried, and scanned by GenePix scanners (Axon Instruments, Inc., Union City, CA). Data were analyzed using ArrayVision FAST software (Schleicher & Schuell, Keene, NH). The detection threshold for each cytokine is determined by the sensitivity of each antibody pair and has been assessed and provided by the manufacturer. The approximate sensitivity for IL-1β/H9252, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12 p70, IL-10, IL-13, TNFR II, TNF-α/H9251, IFN-γ/H9253, and TGF-β is 3 to 15 pg/ml, 30 pg/ml for IP10, sICAM, and VEGF, and 100 pg/ml for IL-12 p40. Changes in cytokine concentrations of over 10-fold are considered significant. As pipetting and repetitive washes during the ELISA create recognizable errors between samples, we chose not to focus on any differences of less than 10-fold.

ELISA. Keratinocytes were infected with WR-VV at an MOI of 10 or irradiated with UVB at 100 J/cm² using a Stratalinker 2400 UV cross-linker with bulbs of peak emission at 312 nm (Stratagene, La Jolla, CA). Data were analyzed using ArrayVision FAST software (Schleicher & Schuell, Keene, NH). The detection threshold for each cytokine is determined by the sensitivity of each antibody pair and has been assessed and provided by the manufacturer. The approximate sensitivity for IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12 p70, IL-10, IL-13, TNFR II, TNF-α, IFN-γ, and TGF-β is ∼3 to 15 pg/ml, 30 pg/ml for IP10, sICAM, and VEGF, and 100 pg/ml for IL-12 p40. Changes in cytokine concentrations of over 10-fold are considered significant. As pipetting and repetitive washes during the ELISA create recognizable errors between samples, we chose not to focus on any differences of less than 10-fold.

RESULTS

VV infects skin cells of different lineages in distinct fashions. To study VV infection of human skin cells, primary cultures of various human skin components, including epidermal keratinocytes (undifferentiated and differentiated), dermal fibroblasts, HMVEC-d, LC (immature and mature), dermal DC, and CLA + skin-homing T cells, were generated and infected with WR-VV in vitro at an MOI of 10. Infection was monitored by the expression of the early and late viral gene products E3L and B5R, respectively, using intracellular staining with anti-E3L and anti-B5R Abs. Among the cell types tested, two distinct patterns of VV infection were observed (Fig. 1A). High levels of both early (E3L) and late (B5R) viral gene expression were detected in keratinocytes, dermal fibroblasts, and HMVEC-d, suggesting productive infection in these cell cultures. High percentages of viral Ag + cells in these cultures indicate these cells are all highly susceptible to vaccinia virus infection. In contrast, early but not late viral gene expression was detected in cells of hematopoietic lineage, including LC, dermal DC, and CLA + T cells (Fig. 1B), indicating abortive infection in these cell types. Except for immature LC, only a small percentage of the hematopoietic cells expressed early viral antigens despite the high infection dose used for this study. This could be due to a low-level virus entry into the cells or to intracellular mechanisms that suppress early viral gene expression. The fluorescence intensities of E3L staining in the limited number of cells supporting early gene expression did not differ significantly from those in the permissive cells (Fig. 1), suggesting that insufficient viral entry into the professional antigen-presenting cells (APCs) and T cells is a limiting factor.
Dermal fibroblasts and HMVEC-d but not keratinocytes support high levels of vaccinia virus replication. Replication of the VV genome occurs after the transcription and translation of early genes, but before that of the intermediate and late genes (31). Thus, the expression of the late viral Ag B5R indicates viral genome replication and potential viral propagation inside the infected cells. To quantitatively analyze viral replication in permissive skin cell cultures, known numbers of keratinocytes, dermal fibroblasts, and HMVEC-d were infected with WR-VV at a low MOI of 0.1 (0.1 PFU per cell). Sixty hours later, the total numbers of virus particles in the cultures were measured by plaque assay and the PFU per input cell was calculated as PFU per sample per number of cells at the beginning of the infection. Cell proliferation during the 60 h was negligible, since the cultures were 85 to 95% confluent at the time of the infection. As shown in Fig. 2, infectious virus particles were produced in all three types of skin cells, but to a different degree in each cell type. While the virus titers in HMVEC-d and dermal fibroblast cultures increased around 2,000-fold (197.8 and 249.1 PFU per cell, respectively) over the 60 h of infection, infection of keratinocytes only yielded 21.8 PFU virus particles per cell (1/10 of the viral yields from HMVEC-d and dermal fibroblasts). The robust vaccinia virus replication in HMVEC-d and dermal fibroblasts is typical for cell lines permissive for exponential viral multiplication. However, the low level of viral replication in keratinocytes was unexpected, since both early and late viral antigens were expressed in keratinocytes at levels comparable to, if not higher than, those seen in dermal fibroblasts and HMVEC-d (Fig. 1A). We have not observed semipermissive infection by VV in any other cell cultures tested. This phenomenon was not due to the early death of the infected keratinocytes, as the cytopathic effect of the virus on keratinocytes was much less severe than on fibroblasts at the end of the 60-h infection (data not shown).

We chose a low virus infection dose (MOI of 0.1) in the above experiment so that the vast majority of the viruses detected 60 h later were newly produced from the cultures instead of the input viruses. It is possible that the low virus yield is due to soluble factors produced from the infected keratinocytes that can inhibit secondary infection in the culture or, alternatively, poor cell-to-cell transmission of VV in keratinocyte culture. To investigate these possibilities, we infected keratinocytes with WR-VV in either fresh keratinocyte medium or conditioned medium from WR-VV-infected keratinocyte cultures. Early and late viral gene expression was detected 20 h postinfection. As shown in Fig. 3, comparable levels of E3L and B5R were detected in keratinocytes infected in fresh medium and conditioned medium from low-dose or high-dose-infected keratinocytes, arguing against the inhibition of secondary infection by keratinocyte soluble factors. We then compared the viral propagation in different cell cultures at a higher virus-to-cell ratio to minimize the need for virus transmission between target cells. Known numbers of keratinocytes, dermal fibroblasts, and HMVEC-d were infected with WR-VV at an MOI of 10 (10 PFU per cell). Sixty hours later, the viral titers were measured by plaque assay and the PFU per input cell was calculated as described before. Increasing the initial viral input did not improve viral yields in all three cell cultures tested (Fig. 4 and 2). This result is expected for HMVEC-d and dermal fibroblasts, as viral yield reaches the plateau level (200 to 300 PFU per cell) over a 60-h incubation regardless of the
input viral dose. In contrast, a 100-fold increase in the infection dose failed to improve the low viral yield (≈20 PFU/cell) in keratinocytes, suggesting that the semipermissive fashion of vaccinia virus infection in keratinocytes is not due to poor virus spreading, but rather reflects intracellular mechanisms to inhibit late-phase viral production.

**Keratinocytes and HMVEC-d show distinct patterns of cytokine production following vaccinia virus infection.** The limited viral replication in keratinocytes suggests that biological functions of keratinocytes, such as cytokine production, may be largely preserved in the presence of the ongoing vaccinia virus infection. To further investigate the functional responses of skin cells following VV infection, supernatant samples from keratinocyte and HMVEC-d cultures were harvested at 24 h postinfection (MOI of 10) and subjected to quantitative analysis for a panel of cytokines and inflammatory mediators. We focused on keratinocytes and endothelial cells, because these two types of cells interact closely with both APCs and T cells in situ and have been implicated in the deviation of cutaneous immune responses toward a Th1 or Th2 phenotype in skin diseases such as psoriasis and atopic dermatitis (37). Sixteen molecules were measured simultaneously using an automated protein array system, and distinct patterns of cytokine production were observed in keratinocytes and HMVEC-d (Fig. 5).

In HMVEC-d, vaccinia virus infection led to greatly reduced production of IL-10, IL-13, TNFR II, and sICAM. With the exception of VEGF, the expression of other cytokines tested remained at low or undetectable levels (Fig. 5 and Table 1). This result was not surprising, as the virus is known to rapidly take over the cellular protein synthesis machinery and switch off the expression of cellular genes in permissive cells. However, in striking contrast, VV infection of keratinocytes resulted in significantly increased (at least 10-fold) levels of TGF-β, IL-10, IL-13, sICAM, and soluble TNFR, with the strongest up-regulation seen in TGF-β (from <15 pg/ml to 3.3 ng/ml). VEGF was the only cytokine tested that was detected at a higher level in HMVEC-d culture supernatant and at a lower level in keratinocyte supernatant. On the other hand, we did not observe any significant changes in levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12, IFN-γ, IP10, and TNF-α following vaccinia virus infection of either keratinocytes or HMVEC-d (Table 1). Keratinocytes have been shown to respond to a variety of stimuli by producing cytokines and chemokines. To further investigate whether the Th2-prone profile of cytokine production from keratinocytes is a common response to general stimuli, or a specific response to vaccinia virus infection, we compared the cytokine production profiles of keratinocytes following VV infection or UVB irradiation. Six different Th1 or Th2 cytokines were measured by ELISA. Consistent with the results shown in Table 1, up-regulation of Th2 cytokines TGF-β, IL-10, and IL-13 was observed in vaccinia virus-infected keratinocytes, while the Th1 cytokines were undetectable in the supernatant. TGF-β was also up-regulated in keratinocytes following UVB irradiation, but at a much lower level than after vaccinia virus infection. Taken together, these results demonstrate that VV infection of keratinocytes leads to up-regulation of TGF-β and Th2 cytokines.
TABLE 1. Cytokine concentrations in supernatants of VV-infected or uninfected keratinocytes and HMVEC-d culturesb

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Keratinocytes</th>
<th>HMVEC-d</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Infected</td>
<td>Uninfected</td>
</tr>
<tr>
<td>IL-1β</td>
<td>5.9</td>
<td>5.6</td>
</tr>
<tr>
<td>IL-2</td>
<td>7.8</td>
<td>&lt;3</td>
</tr>
<tr>
<td>IL-4</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
<tr>
<td>IL-5</td>
<td>6.5</td>
<td>&lt;3</td>
</tr>
<tr>
<td>IL-6</td>
<td>41.4</td>
<td>&lt;5</td>
</tr>
<tr>
<td>IL-8</td>
<td>121.1</td>
<td>50.4</td>
</tr>
<tr>
<td>IL-12 p40</td>
<td>225.8</td>
<td>&lt;100</td>
</tr>
<tr>
<td>IL-12 p70</td>
<td>29.2</td>
<td>22.7</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>&lt;3</td>
<td>&lt;3</td>
</tr>
<tr>
<td>IP10</td>
<td>&lt;30</td>
<td>64.3</td>
</tr>
<tr>
<td>TNF-α</td>
<td>17.5</td>
<td>5.4</td>
</tr>
</tbody>
</table>

a Less than the detection threshold for the given cytokine.
b Keratinocytes and HMVEC-d were either untreated or infected with VV at an MOI of 10 and cultured at 37°C for 24 h. Cytokine concentrations (pg/ml) in the supernatant samples were measured by MicroSpot ELISA array as described in Materials and Methods.

DISCUSSION

This is the first comprehensive study of vaccinia virus infection in healthy human skin cells. Two distinct patterns of infection were observed in different types of skin cells. Skin cells of hematopoietic lineage, such as LC and dermal DC, are relatively resistant to VV infection, and those that were infected did not support VV late gene expression or viral replication. This is consistent with a previous report from Bhardwaj’s group that showed VV abortively infects human monocyte-derived DC (14). The resistance and abortive infection may allow the infected skin APCs to survive long enough to execute their functions—that is, to carry antigens to draining lymph nodes, or to activate skin-infiltrating lymphocytes in situ, and induce protective T-cell immunity. This notion is supported by the observation that VV-infected mature monocyte-derived DC cultures induce strong CTL activity (7, 14). In contrast, VV readily establishes productive infection in epidermal keratinocytes, dermal fibroblasts, and HMVEC-d. Interestingly, despite the comparable levels of viral antigen expression among the permissive cell cultures, keratinocytes did not support a high level of VV replication as seen in dermal fibroblasts and HMVEC-d (Fig. 2). It is not clear at present how keratinocytes suppress vaccinia virus replication. Low-level virus production in keratinocytes is not due to inhibitory soluble factors from the infected cells (Fig. 3), nor inhibition of cell-to-cell spread (Fig. 4), suggesting intracellular pathways exist to limit VV replication at a late stage. It is possible that semipermissive infection of keratinocytes may serve as a protective mechanism to prevent rapid virus production and dissemination in the skin surface layers following vaccinia virus inoculation.

In addition to providing a primary physical barrier between the body and the environment, skin cells also function in initiating innate inflammatory responses and shaping adaptive immune responses by producing and responding to inflammatory and immunoregulatory mediators in response to environmental insults (23, 37, 41, 45). We compared the expression levels of 16 cytokines and inflammatory mediators in keratinocytes and HMVEC-d before and after VV infection. Our data show that while release of these factors is globally downregulated in the infected endothelial cells, there is a remarkable up-regulation of multiple immunoregulatory and Th2-promoting cytokines, including TGF-β, IL-10, and IL-13, in the infected keratinocytes. Each of these cytokines was up-regulated by more than a factor of 10 and TGF-β by much more. TGF-β is in general considered to be an inhibitory cytokine for the development of inflammation and Th1 responses. While TGF-β attracts neutrophils and lymphocytes to the injury site at early stages of inflammation, it inhibits their proliferation and function at later stages (29). The negative modulating role of TGF-β in Th1-dominated diseases has been well documented in autoimmune disease models using TGF-β-deficient animals (26). In addition, studies of lung epithelium from asthmatic patients suggest a role for TGF-β1 in the pathogenesis of this characteristically Th2-dominated disease (43, 46). Recently, TGF-β has also been shown to be important in both the generation and the action of regulatory CD4+ and CD8+ T cells (18, 32). IL-10 is one of the best-studied suppressor cytokines for both innate and adaptive immune functions. It potently inhibits Th1 cells as well as the production of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-α (30). IL-10 produced from VV-infected keratinocytes may serve to prevent the induction of the proinflammatory cytokines. Indeed, we did not detect significant production of either Th1 or proinflammatory cytokines from vaccinia virus-infected keratinocytes (Table 1). Finally, IL-13 is also involved in the development of the Th2 response, with functions paralleling those of IL-4 (11, 28). These Th2 cytokines have been implicated in the pathogenesis of atopic dermatitis (1, 9, 24). We also observed significant up-regulation of sICAM and TNFR from the vaccinia virus-infected keratinocytes. Blocking T-cell LFA-1 locally by sICAM and binding of TNF-α by soluble TNFR may also contribute to local immunosuppression and are likely to enhance the inhibitory effects of the negative regulatory cytokines, such as IL-10, TGF-β, and IL-13 (5, 6, 17).

We did not observe any significant changes in levels of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-12, IFN-γ, IP10, and TNF-α following vaccinia virus infection of either keratinocytes or HMVEC-d (Table 1). However, these data need to be interpreted with caution, since a number of poxvirus early genes encode antagonistic cytokine receptor homologues that can...
specifically bind to several regulatory cytokines, including IL-1β, IFN-α, -β, -γ, and TNF-α (3, 4, 12, 22). These viral gene products may block the detection by MAbs used in our detection assay. In unpublished studies, we have shown that coinfection of supernatant from VV-infected DC cultures with TNF-α-containing medium completely abrogated the ELISA detection of TNF-α (unpublished data). Rapid production of cytokine receptor homologues following the infection of target cells may provide the virus an opportunity to evade host innate as well as adaptive immune responses in the early stages following viral inoculation. Alternatively, the immunoregulatory and Th2 cytokines and chemokines from the infected keratinocytes may directly inhibit the production of some proinflammatory and Th1-inducing cytokines in the same cells.

We compared cytokine production from UVB-irradiated or VV-infected keratinocytes (Table 2). TNF-α, instead of IL-13 and IL-10, was produced from UVB-irradiated cells, and the induction of TGF-β was much weaker in the irradiated cells than in VV-infected cells. In addition, the IL-1 and IL-8 family of chemokines has been shown to be up-regulated following UV irradiation of keratinocytes (10, 27), and we failed to detect significant increases of these cytokines in vaccinia virus-infected keratinocyte culture supernatants. These results suggest that the up-regulation of the Th2 cytokines is not a response of keratinocytes to stimulation in general, but rather a specific response of these cells to VV infection. This notion is supported by studies of cytokine production from keratinocytes infected by other skin-tropic viruses. Increased Th1 cytokine IFN-γ, TNF-α, and IL-6 expression levels were observed in keratinocytes following variella-zoster virus infection (33). On the other hand, human papilloma virus 2/27/57 infection led to an induction of IL-6, IL-10, and IFN-γ and an up-regulation of TGF-β (20).

While in many patients inoculation with smallpox vaccine induces local pain and swelling and systemic symptoms associated with viremia, the vast majority of vaccines generate potent and long-lasting protective immunity against variola virus without any negative clinical consequence. It is reasonable to suspect that the strategies employed by vaccinia virus to evade the immune response, both previously described (40) and newly reported here, allow local replication of the virus such that a pox reaction and viremia can occur. However, they are insufficient to cause significant morbidity and mortality in patients with intact immune systems. Currently, it is still unclear how VV rapidly induces strong immune responses while utilizing multiple elegant strategies to evade the immune system. It will be important to investigate whether the intact physical barrier provided by the semipermissive keratinocytes is essential for preventing undesirable rapid virus dissemination and whether the presence of potent immune effector cells in vivo may overcome or reverse the pattern of the immune-modulating molecule production in skin following vaccinia virus infection.

Taken together, this is the first study to show that VV induces immunoregulatory and Th2-polarizing cytokines from infected keratinocytes. This may represent a novel VV strategy to alter the host immune response in favor of its own survival, albeit local and temporary in the majority of patients. It is currently under investigation whether the soluble factors produced from vaccinia virus-infected keratinocytes could in turn modulate the maturation, differentiation, and functions of DC and T cells. It has been shown previously that VV counteracts the host immune response by blocking dendritic cell maturation, encoding soluble antagonistic receptor homologues for proinflammatory mediators and Th1 cytokines, and producing a soluble inhibitor that sequesters CC chemokines (2–4, 14, 36). Our study suggests that the induction of immunoregulatory cytokines by infected keratinocytes may work in concert with these immune evasion strategies to create a local cutaneous microenvironment that would antagonize virus-controlling Th1 and CTL responses and favor local viral replication.

In immunocompetent individuals, the host immune system can usually overcome these immune evasion mechanisms and completely clear the infection even after it has been present for several days. However, in patients with compromised cutaneous immune surveillance and impaired ability to regulate the Th1/Th2 balance (e.g., patients with atopic dermatitis), these immune evasion strategies may permit unrestrained viral growth and dissemination, resulting in the clinical condition known as eczema vaccinatum. Engineering recombinant VV strains that block immunoregulatory or Th2-polarizing cytokines may represent a new strategy for developing a safe smallpox vaccine.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health grant 1U19AI57330 to T. S. Kupper and by a research grant from the Dermatology Foundation to L. Liu.

We thank Elot Eriksson (Department of Plastic Surgery, Brigham and Women’s Hospital, Boston, MA) for providing skin tissues, Jo-Ellen Murphy for preparing primary keratinocyte and fibroblast cell cultures, and Jay Omobono for help in editing the manuscript.

REFERENCES


